Endogenex, Inc.
5
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
Role: lead
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
Role: lead
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
Role: lead
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
Role: lead
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Role: lead
All 5 trials loaded